June 22, 2021 in News | Comments Off on ARCHER project awarded €900K for a product to prevent catheter-related bloodstream infections
We are delighted to share about our joint project with TADA Medical, Sweden as a potential solution to the problem of hospital acquired infections (HAIs) and catheter-related bloodstream infections (CRBSIs). The collaborative innovation project has been awarded €900K funding from the programme Eurostars-2 (co-funded by EUREKA member countries and EU H2020 programme framework).
Eurostars is the largest international funding programme for SMEs wishing to collaborate on R&D projects that create innovative products, processes or services for commercialisation.
The project´s outcome will be a potential solution that simultaneously combines the benefits of Tada Medical´s breakaway connector ReLink, that prevents dislodgement of the IV tube, with Amicoat´s antimicrobial peptide AMC-109 which prevents growth of bacteria and fungi (also when they occur in biofilms) and viruses.
The two-year collaborative project will combine two patented technologies to develop a family of breakaway connectors with antimicrobial properties that can be adopted for therapies ranging from rapid blood transfusion, dialysis, treatment of large animals to those requiring central venous catheters, neonatal care and insulin pumps.
We are extremely happy about this joint project and sharing resources and manufacturing solutions to tackle the unmet clinical needs. As an outcome, we intend to commercialise this technology and deliver significant value to healthcare providers globally.
Job Opening: Vice President Research & Development
Amicoat is heading towards an exciting phase where we want to strengthen our technology and. . .
Read moreNy sjef med drømmebakgrunn
Selskapet Amicoat i Forskningsparken produserer et bakteriedrepende stoff som er forsket frem ved Universitetet i. . .
Read moreAmicoat Media Inquiries
Amicoat AS
Oslo Science Park
Lensmannslia 4
1386 Asker, Norway
media: media@amicoat.com
Contact UsAmicoat will not pass on your contact information to third parties or use the contact information provided for purposes other than keeping you informed about company news.
An email confirmation will be sent to you shortly. If your internet provider filters incoming emails, please add media@amicoat.com to your list of approved senders to ensure that you receive the newsletter.